With its oncology drugs in decline and a string of recent failures on Alzheimer's, the Swiss giant veers into Inflammatory Bowel Diseases (IBD) by securing for more than 7 billion the U.S. rights to an investigational new drug.
The French company has announced the spin-off of its consumer unit and increased investment in the development of new immunology and inflammation drugs, but must abandon its profit targets for the next two years
DARWIN EU, acronym for Data Analysis and Real World Interrogation Network, is the new long-term project of EMA, the European Medicines Agency. The objective...